US regulators rein in vaccine rush
The US Food and Drug Administration has released stricter guidelines for drug developers who might seek an emergency-use authorization (EUA) for the COVID-19 vaccine. Manufacturers must now collect safety data on at least half of their clinical-trial participants for two months after they receive their final dose. (Most of the vaccine frontrunners require two doses.) And immunologist Moncef Slaoui — the science leader of the US government’s ambitious vaccine project, Operation Warp Speed — says the effort has urged manufacturers to refrain from pursuing an EUA until they are “able to immunize at least a relevant fraction of the population”. Approval of a vaccine that wasn’t widely available would be “a major disappointment” to the public, says Slaoui.STAT | 5 min read
No hay comentarios:
Publicar un comentario